Pearl Therapeutics
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Pearl Therapeutics sits in the top decile of US sponsors by registered trial count (#526 of 15,742 sponsors by registered trial count).
Pearl Therapeutics: 31 sponsored US clinical trials, none currently recruiting.
Pearl Therapeutics sponsors 31 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 30 completed. 12 of these trials are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Chronic Obstructive Pulmonary Disease, with 2 trials.
Top-decile sponsor footprint
Pearl Therapeutics ranks in the top decile of sponsors by registered trial count (#526 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
30 of 31 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (96.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
31 total, page 1 of 1
Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma
NCT03358147
A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010
NCT03311373
A Study to Assess the PK and Safety of PT010 in Subjects With COPD Following Single and Repeat Dose
NCT03250182
Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD
NCT02685293
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
NCT02766608
A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)
NCT02727660
A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)
NCT02497001
Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
NCT02536508
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)
NCT02465567
Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma
NCT02433834
Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD
NCT02454959
Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD
NCT02343458
Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD
NCT02268396
Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT02196077
Randomized, Crossover Safety and Pharmacokinetics Study of PT010
NCT02197975
PK Study of PT003 and PT001 in Japanese Healthy Subjects
NCT02196714
Pharmacokinetics and Safety Study of PT010 in Healthy Subjects
NCT02189304
Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD
NCT02109406
Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
NCT02105012
Phase I Study Evaluating the Safety and Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI) in Healthy Volunteers
NCT01980615
Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)
NCT01970878
Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)
NCT01854658
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
NCT01854645
Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT01587079
PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD
NCT01566773
PT003 MDI Dose Confirmation Study
NCT01349816
PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT01350128
PT003 MDI Cardiovascular Safety Study
NCT01349803
PT005 MDI Dose Ranging Versus Foradil Aerolizer Study
NCT01349868
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT01085045
Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00871182
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 12 |
| Phase 3 | 12 |
Therapeutic Areas
How the Pearl Therapeutics early-phase archive is shaped
31 indexed studies, none listed as recruiting (0% open); 30 completed (97%).
Phase mix: 12 late (III/IV) vs 19 early (I/II) (early-phase heavy).
Top condition: Chronic Obstructive Pulmonary Disease (2 trials), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Pearl Therapeutics: archived-pipeline peers nationwide
Peers matched on 31 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Pearl Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 31 archived trials
- Children's Hospitals and Clinics of Minnesota · 31 trials · 10% recruiting
- Cook Group Incorporated · 31 trials · 0% recruiting
- Cytokinetics · 31 trials · 10% recruiting
- Halozyme Therapeutics · 31 trials · 3% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Pearl Therapeutics page
31 registered trials is a research-attention snapshot, not an endorsement of Pearl Therapeutics or any single study.
- None of Pearl Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Chronic Obstructive Pulmonary Disease is the condition Pearl Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Chronic Obstructive Pulmonary Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Pearl Therapeutics pipeline card: 31 registered trials from official public datasets.Report a data error.